At-the-Market (ATM) agreement with Acuity Capital
Filed with ASX · · 2 pages · English
Earlier from Noxopharm
- Sofra breakthrough science publish in major medical journal
- December 2025 Quarterly Activities Report and Appendix 4C
- HERACLES clinical trial successfully completed
- HERACLES clinical trial Update 5
- First dose in HERACLES clinical trial Part Two
Later from Noxopharm
- R&D rebate strengthens cash position
- Appendix 4D and FY2026 Half Year Financial Report
- Resignation of Chief Executive Officer
- Noxopharm appoints Dr Olivier Laczka as new CEO
- Positive SOF-SKN dosing data shows prolonged skin retention
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm